Europe pharmaceutical manufacturing industry accounted for $84.31 billion in 2020 and will grow by 12.9% annually over 2020-2030 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.
Highlighted with 36 tables and 64 figures, this 131-page report “Europe Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Industry Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Industry Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.
Based on Formulation, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Tablets
• Capsules
• Injectable
• Sprays
• Suspensions
• Powders
• Other Formulations
Based on Route of Administration, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Oral Medicine
• Topical Medicine
• Parenteral Medicine
• Inhalations
• Other Routes of Administration
Based on Age Group, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Children & Adolescents
• Adults
• Geriatric
Based on Therapeutic Application, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Cardiovascular Diseases
• Pain
• Diabetes
• Cancer
• Respiratory Diseases
• Neurological Diseases
• Orthopedics
• Other Applications
Based on Drug Type, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Based on Distribution Channels, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• Retail Channels
• Non-retail Channels
Based on Manufacturing Facility, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
• In-house Facility
• Outsourced Facility
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players.
Specifically, potential risks associated with investing in Europe pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Industry Research Methodology 11
1.2.2 Industry Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 Industry Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Industry Overview and Dynamics 20
2.1 Industry Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Industry 24
2.2 Major Growth Drivers 26
2.3 Industry Restraints and Challenges 29
2.4 Emerging Opportunities and Industry Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Europe Industry by Formulation 40
3.1 Industry Overview by Formulation 40
3.2 Tablets 42
3.3 Capsules 43
3.4 Injectable 44
3.5 Sprays 45
3.6 Suspensions 46
3.7 Powders 47
3.8 Other Formulations 48
4 Segmentation of Europe Industry by Route of Administration 49
4.1 Industry Overview by Route of Administration 49
4.2 Oral Medicine 51
4.3 Topical Medicine 52
4.4 Parenteral Medicine 53
4.5 Inhalations 54
4.6 Other Routes of Administration 55
5 Segmentation of Europe Industry by Age Group 56
5.1 Industry Overview by Age Group 56
5.2 Children & Adolescents 58
5.3 Adults 59
5.4 Geriatric 60
6 Segmentation of Europe Industry by Therapeutic Application 61
6.1 Industry Overview by Therapeutic Application 61
6.2 Cardiovascular Diseases 63
6.3 Pain 64
6.4 Diabetes 65
6.5 Cancer 66
6.6 Respiratory Diseases 67
6.7 Neurological Diseases 68
6.8 Orthopedics 69
6.9 Other Applications 70
7 Segmentation of Europe Industry by Drug Type 71
7.1 Industry Overview by Drug Type 71
7.2 Branded Prescription Drugs 73
7.3 Generic Prescription Drugs 74
7.4 OTC Drugs 75
8 Segmentation of Europe Industry by Distribution Channels 76
8.1 Industry Overview by Distribution Channels 76
8.2 Retail Channels 78
8.3 Non-retail Channels 79
9 Segmentation of Europe Industry by Manufacturing Facility 80
9.1 Industry Overview by Manufacturing Facility 80
9.2 In-house Facility 82
9.3 Outsourced Facility 83
10 European Industry 2020-2027 by Country 84
10.1 Overview of European Industry 84
10.2 UK 87
10.3 France 89
10.4 Germany 91
10.5 Spain 93
10.6 Italy 95
10.7 Russia 97
10.8 Rest of European Industry 99
11 Competitive Landscape 101
11.1 Overview of Key Vendors 101
11.2 New Product Launch, Partnership, Investment, and M&A 104
11.3 Company Profiles 105
Abbott Laboratories 105
Aenova Group 107
Amgen 108
AstraZeneca 109
Catalent Inc. 110
Eli Lilly and Company 111
F. Hoffmann-La Roche Ltd. 112
Gilead Sciences 113
GlaxoSmithKline plc 114
Johnson & Johnson 115
Lonza Group 116
Lupin 117
Merck & Co., Inc. 118
Novartis AG 119
Novo Nordisk 120
Pfizer, Inc. 121
Roche 122
Sanofi SA 123
Takeda 124
12 Investing in Europe Industry: Risk Assessment and Management 125
12.1 Risk Evaluation of Europe Industry 125
12.2 Critical Success Factors (CSFs) 128
Related Reports and Products 131
Table 1. Snapshot of Europe Pharmaceutical Manufacturing Industry in Balanced Perspective, 2020-2027 18
Table 2. Growth Rate of World Real GDP, 2017-2021 22
Table 3. Main Product Trends and Industry Opportunities in Europe Pharmaceutical Manufacturing Industry 32
Table 4. Europe Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 40
Table 5. Europe Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 49
Table 6. Europe Pharmaceutical Manufacturing Industry by Age Group, 2017-2027, $ bn 56
Table 7. Europe Pharmaceutical Manufacturing Industry by Therapeutic Application, 2017-2027, $ bn 61
Table 8. Europe Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 71
Table 9. Europe Pharmaceutical Manufacturing Industry by Distribution Channels, 2017-2027, $ bn 76
Table 10. Europe Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2017-2027, $ bn 80
Table 11. Europe Pharmaceutical Manufacturing Industry by Country, 2017-2027, $ bn 86
Table 12. UK Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 88
Table 13. UK Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 88
Table 14. UK Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 88
Table 15. France Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 90
Table 16. France Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 90
Table 17. France Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 90
Table 18. Germany Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 92
Table 19. Germany Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 92
Table 20. Germany Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 92
Table 21. Spain Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 94
Table 22. Spain Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 94
Table 23. Spain Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 94
Table 24. Italy Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 96
Table 25. Italy Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 96
Table 26. Italy Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 96
Table 27. Russia Pharmaceutical Manufacturing Industry by Formulation, 2017-2027, $ bn 98
Table 28. Russia Pharmaceutical Manufacturing Industry by Route of Administration, 2017-2027, $ bn 98
Table 29. Russia Pharmaceutical Manufacturing Industry by Drug Type, 2017-2027, $ bn 98
Table 30. Pharmaceutical Manufacturing Industry in Rest of Europe by Country, 2017-2027, $ bn 100
Table 31. Abbott Laboratories: Company Snapshot 105
Table 32. Abbott Laboratories: Business Segmentation 105
Table 33. Abbott Laboratories: Product Portfolio 106
Table 34. Abbott Laboratories: Revenue, 2017-2019, $ bn 106
Table 35. Risk Evaluation for Investing in Europe Industry, 2020-2027 126
Table 36. Critical Success Factors and Key Takeaways 129
